BioCentury
ARTICLE | Company News

Akshaya Bio Inc., Nuron deal

March 12, 2012 7:00 AM UTC

Nuron received exclusive, worldwide rights from Akshaya to Chimigen multi-antigen vaccines to treat HBV. Nuron, which said it expects to begin a Phase I trial of the lead HBV vaccine next year, also ...